Updated results from the phase 3 Breast Cancer Trials of Oral Everolimus (BOLERO-2) showed that adding everolimus to the treatment regimen with the aromatase inhibitor exemestane more than doubled progression-free survival (PFS) in patients with advanced estrogen receptor (ER)-positive breast cancer whose disease had become refractory to hormonal therapy.